Drug interactions
Elvitegravir / cobicistat / emtricitabine / tenofovir df + Fluticasone furoate
Severity: Major
Elvitegravir / cobicistat / emtricitabine / tenofovir df and Fluticasone furoate: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
The cobicistat component strongly inhibits CYP3A and increases fluticasone exposure. Iatrogenic Cushing syndrome and adrenal suppression are recognized with such combinations.
What this interaction means in plain words
Elvitegravir / cobicistat / emtricitabine / tenofovir df and Fluticasone furoate can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
Cobicistat inhibits CYP3A4, markedly reducing fluticasone clearance.
What to do
Avoid long-term coadministration and use beclomethasone or another alternative. If unavoidable, monitor for Cushingoid features and adrenal suppression.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Elvitegravir / cobicistat / emtricitabine / tenofovir df and Fluticasone furoate, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Frequently asked questions
Can I take Elvitegravir / cobicistat / emtricitabine / tenofovir df with Fluticasone furoate?
MediHelp rates the interaction as major. Elvitegravir / cobicistat / emtricitabine / tenofovir df and Fluticasone furoate can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. The cobicistat component strongly inhibits CYP3A and increases fluticasone exposure. Iatrogenic Cushing syndrome and adrenal suppression are recognized with such combinations.
How serious is the interaction between Elvitegravir / cobicistat / emtricitabine / tenofovir df and Fluticasone furoate?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid long-term coadministration and use beclomethasone or another alternative. If unavoidable, monitor for Cushingoid features and adrenal suppression.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
